Parkinson’s disease (PD) is a neurodegenerative illness that affects the central nervous system and leads to a gradual degeneration of neurons that results in movement slowness, mental health problems, speaking difficulties, etc. In the past 20 years, the frequency of PD has doubled. Global estimates revealed that over 8.5 million cases have been identified so far. Thus, early and accurate detection of PD is crucial for treatment. Traditional detection methods are subjective and prone to delays, as they are reliant on clinical evaluation and imaging. Alternatively, artificial intelligence (AI) has recently emerged as a transformative technology in the healthcare sector, showing decent and promising results. However, an effective algorithm needs to be investigated for the most accurate prediction of a particular disease. Thus, this paper explores the ability of different machine learning algorithms in regard to the effective detection of PD. A total of 26 algorithms were implemented using the Scikit-Learn library on the Oxford PD detection dataset. This is a collection of 195 voice measurements recorded from 31 individuals, of which 23 have PD. The implemented algorithms are logistic regression, decision tree, k-nearest neighbors, random forest, support vector machine, Gaussian naïve bayes, multi-layered perceptron (MLP), extreme gradient boosting, adaptive boosting, stochastic gradient descent, gradient boosting machine, extra tree classifier, light gradient boosting machine, categorical boosting, Bernoulli naïve bayes, complement naïve bayes, multinomial naïve bayes, histogram-based gradient boosting, nearest centroid, radius neighbors classifier, logistic regression with elastic net regularization, extreme learning machine, ridge classifier, huber classifier, perceptron classifier, and voting classifier. Among them, MLP outperformed the other algorithms with a testing accuracy of 95%, precision of 94%, sensitivity of 100%, F1 score of 97%, and AUC of 98%. Thus, it successfully discriminates healthy individuals from those with PD, thereby helping for accurate early detection of PD for new patients using their voice measurements.

Brain tumors are critical neurological disorders affecting mankind. The Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) scans play an important role in diagnosing brain tumors, but need an expert interpretation. Although deep learning methods can automate tumor detection, their lack of interpretability and clinical trust remains a major limitation. To address this concern, this paper presents a BrainTumorClassificationNetwork‐Convolutional Neural Network (BTCNet‐CNN) model with several layers for detecting and classifying MRI scanned images into four categories: glioma, meningioma, no tumor, and pituitary. The model was trained and evaluated on a publicly available dataset comprising 5824 MRI images. Augmentation techniques such as horizontal flipping, random rotations, zooming, shifting, and shearing were implemented on the training set, increasing data diversity and enhancing BTCNet‐CNN's robustness to variations in tumor orientation, scale, and position. To evaluate the effectiveness of the proposed model, various popular pre‐trained networks such as ResNet50 and InceptionV3 are also implemented on the dataset with metrics such as accuracy, loss, precision, recall, F1 score, and AUROC. Among these three models, the BTCNet‐CNN has achieved superior performance with an accuracy of 99.31%, a loss of 0.118, and an average precision, recall, and F1 score of 99.25%, 99.25%, and 99.5%, respectively, on the unseen data. Statistical significance was evaluated using McNemar's test, confirming that BTCNet‐CNN's predictions are significantly better than those of ResNet50 and InceptionV3 ( p < 0.05). To enhance trust and interpretability of models' decisions, various Explainable AI (XAI) techniques, including Occlusion Sensitivity, LIME, Smooth Gradients, and Saliency Maps, were integrated. Finally, a Streamlit‐based web application was developed to facilitate real‐time prediction and visualization, ensuring practical applicability in clinical diagnosis.

Alzheimer’s disease (AD), an intense neurological illness, severely impacts memory, behavior, and personality, posing a growing concern worldwide due to the aging population. Early and accurate detection is crucial as it enables preventive measures. However, current diagnostic methods are often inaccurate in identifying the disease in its early stages. Although deep learning-based bioimaging has shown promising results in medical image classification, challenges remain in achieving the highest accuracy for detecting AD. Existing approaches, such as ResNet50, VGG19, InceptionV3, and AlexNet have shown potential, but they often lack reliability and accuracy due to several issues. To address these gaps, this paper suggests a novel bioimaging technique by developing a custom Convolutional Neural Network (CNN) model for detecting AD. This model is designed with optimized layers to enhance feature extraction from medical images. The experiment’s first phase involved the construction of the custom CNN structure with three max-pooling layers, three convolutional layers, two dense layers, and one flattened layer. The Adam optimizer and categorical cross-entropy were adopted to compile the model. The model’s training was carried out on 100 epochs with the patience set to 10 epochs. The second phase involved augmentation of the dataset images and adding a dropout layer to the custom CNN model. Moreover, fine-tuned hyperparameters and advanced regularization methods were integrated to prevent overfitting. A comparative analysis of the proposed model with conventional models was performed on the dataset both before and after the data augmentation. The results validate that the proposed custom CNN model significantly overtakes pre-existing models, achieving the highest validation accuracy of 99.53% after data augmentation while maintaining the lowest validation loss of 0.0238. Its precision, recall, and F1 score remained consistently high across all classes, with perfect scores for the Moderate Demented and Non-Demented categories after augmentation, indicating superior classification capability.

Thyroid cancer is the most common type of endocrine cancer. Most cases are called differentiated thyroid cancer (DTC), which includes papillary, follicular, and hurthle cell types. DTC usually grows slowly and has a good prognosis, especially when found early and treated with surgery, radioactive iodine, and thyroid hormone therapy. However, cancer can come back sometimes even years after treatment. This recurrence can appear as abnormal blood tests or as lumps in the neck or other parts of the body. Being able to predict and detect these recurrences early is important for improving patient care and planning follow-up treatment. In this view, this research explores different machine learning algorithms and neural networks to effectively predict DTC recurrence. A total of 17 classifiers were utilized for the experiment, namely, logistic regression, random forest, k-nearest neighbours, Gaussian naïve Bayes, multi-layered perceptron, extreme gradient boosting, adaptive boosting, gradient boosting classifier, extra tree classifier (ETC), light gradient boosting machine, categorical boosting, Bernoulli naïve Bayes, complement naïve Bayes, multinomial naïve Bayes, histogram-based gradient boosting, and nearest centroid, followed by building an artificial neural network. Among the classifiers, ETC performed best with 95.3% accuracy, 95.1% precision, 87.92% recall, 98.18% specificity, 91.21% F1-score, 98.84% AUROC and 97.66% AUPRC on the first dataset, and 99.47% accuracy, 94.83% precision, 98.62% sensitivity, 99.54% specificity, 96.65% F1-score, 99.95% AUROC, and 99.37% AUPRC on the second dataset. To improve model interpretability, Shapley Additive Explanations (SHAP) was also used to explain the contribution of each clinical feature to the model’s predictions, allowing for transparent, patient-specific insights into which factors were most important for predicting recurrence, thereby supporting the proposed model’s clinical relevance.